Why Is Bio-Rad (BIO) Up 7.8% Since Last Earnings Report?

Revenues of $610.8 million in the first quarter missed the Zacks Consensus Estimate by 0.2%. The figure dropped 9.8% from the year-ago quarter's levels (down 9.6% at the constant exchange rate or CER). VGM Scores The cumulative net cash flow from operating activities at the end of the first quarter was$ 697.9 million compared with the year-ago figure of $981.2 million. Bio-Rad belongs to the Zacks Medical - Products industry. Another stock from the same industry, Boston Scientific (BSX) , has gained 4.4% ov ...